EP3326622
MODIFIED AXL PEPTIDES AND THEIR USE IN INHIBITION OF AXL SIGNALING IN ANTI-METASTATIC THERAPY
Status:
EP einkaleyfi: Þýðing ekki lögð innEP appl. date:
12.12.2013EP published:
20.1.2021EP application number:
17196662.5
EPO information:
European Patent Register
Max expiry date:
11.12.2033
Title:
MODIFIED AXL PEPTIDES AND THEIR USE IN INHIBITION OF AXL SIGNALING IN ANTI-METASTATIC THERAPY
Timeline
Today
12.12.2013EP application
20.1.2021EP Publication
Owner
Name:
The Board of Trustees of the Leland Stanford Junior UniversityAddress:
Office of the General Counsel Building 170, Third Floor, Main Quad P.O. Box 20386, Stanford, CA 94305-2038, US
Name:
Aravive Biologics, Inc.Address:
LyondellBasell Tower 1221 McKinney, Suite 3200, Houston, TX 77010, US
Inventor
Name:
GIACCIA, Amato J.Address:
Stanford, CA California 94305, US
Name:
RANKIN, Erinn BrunoAddress:
Waltham, MA Massachusetts 02452, US
Name:
COCHRAN, Jennifer R.Address:
Stanford, CA California 94305, US
Name:
JONES, DouglasAddress:
Newton, MA Massachusetts 02458, US
Name:
KARIOLIS, MihalisAddress:
San Mateo, CA California 94401, US
Name:
FUH, KatherineAddress:
St. Louis, MO Missouri 63108, US
Name:
MIAO, YuAddress:
Sunnyvale, CA California 94087, US
Name:
HERSHENSON, SusanAddress:
Palo Alto, CA California 94301, US
Priority
Number:
201261737276 PDate:
14.12.2012Country:
US
Classification
Categories:
A61K 31/00, C07K 14/47, C07K 16/18, C07K 16/28, C07K 16/40, A61P 35/00